Published in BMJ on August 14, 2014
The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil | NCT03144596
The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study. BMJ (2015) 1.50
The study about physical activity for subjects with prevention of benign prostate hyperplasia. Int Neurourol J (2014) 0.86
Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Eur Urol (2016) 0.79
Maximum Urine Flow Rate of Less than 15ml/Sec Increasing Risk of Urine Retention and Prostate Surgery among Patients with Alpha-1 Blockers: A 10-Year Follow Up Study. PLoS One (2016) 0.78
Prevalence and factor association of premature ejaculation among adult Asian males with lower urinary tract symptoms. Prostate Int (2015) 0.76
Men's preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment. Patient Prefer Adherence (2016) 0.75
Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Can Urol Assoc J (2017) 0.75
Resveratrol-Mediated Repression and Reversion of Prostatic Myofibroblast Phenoconversion. PLoS One (2016) 0.75
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report (2008) 19.25
Liver fibrosis. J Clin Invest (2005) 17.27
The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol (1992) 13.63
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg (2005) 10.99
The development of human benign prostatic hyperplasia with age. J Urol (1984) 8.29
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med (1998) 6.44
Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA (1993) 5.77
The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med (1996) 5.06
Saw palmetto for benign prostatic hyperplasia. N Engl J Med (2006) 4.99
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA (2006) 4.15
The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol (1993) 3.66
Integrating mechanisms of pulmonary fibrosis. J Exp Med (2011) 3.57
Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol (2008) 3.37
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol (2009) 3.31
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology (2002) 2.94
Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Eur Urol (2008) 2.86
Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. J Urol (2008) 2.83
A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol (2006) 2.74
The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int (2009) 2.63
Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. Eur Urol (2007) 2.61
Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA (1998) 2.46
Photoselective vaporization with the green light laser vs transurethral resection of the prostate for treating benign prostate hyperplasia: a systematic review and meta-analysis. BJU Int (2012) 2.42
Urologic diseases in america project: benign prostatic hyperplasia. J Urol (2008) 2.38
Prostatic fibrosis is associated with lower urinary tract symptoms. J Urol (2012) 2.37
Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol (2001) 2.37
Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol (2002) 2.27
Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population. Urology (2011) 2.26
Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab (2006) 2.17
Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl (1989) 2.12
Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol (2007) 2.04
Efficacy of nondrug lifestyle measures for the treatment of nocturia. J Urol (2010) 1.94
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn (2011) 1.93
Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol (2001) 1.92
Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology (1998) 1.90
High-power thulium fiber laser ablation of urinary tissues at 1.94 microm. J Endourol (2005) 1.90
Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int (2011) 1.84
Maximum and average urine flow rates in normal male and female populations--the Liverpool nomograms. Br J Urol (1989) 1.75
The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol (1994) 1.71
Obesity and benign prostatic hyperplasia. Am J Epidemiol (1994) 1.71
Systematic review and meta-analysis of the clinical effectiveness of bipolar compared with monopolar transurethral resection of the prostate (TURP). BJU Int (2013) 1.69
Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ (2006) 1.66
Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.65
A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol (2012) 1.61
Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol (2003) 1.58
Lower urinary tract symptoms increase the risk of falls in older men. BJU Int (2009) 1.53
The efficacy and safety of combined therapy with α-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. J Urol (2013) 1.52
Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol (1975) 1.51
Pressure flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. Rev Urol (2005) 1.49
Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA (2011) 1.46
High power potassium-titanyl-phosphate laser vaporization prostatectomy. J Urol (2000) 1.44
A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol (1978) 1.44
Promising molecular targets and biomarkers for male BPH and LUTS. Curr Urol Rep (2013) 1.43
Systematic review and meta-analysis of Transurethral Needle Ablation in symptomatic Benign Prostatic Hyperplasia. BMC Urol (2006) 1.39
Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am (1990) 1.38
II. The Question of Castration for Enlarged Prostate. Ann Surg (1896) 1.37
Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol (2005) 1.36
Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med (2009) 1.32
The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int (2005) 1.27
Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology (2003) 1.23
Clinical experience with intraoperative floppy-iris syndrome. Results of the 2008 ASCRS member survey. J Cataract Refract Surg (2008) 1.21
Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia. J Urol (1984) 1.19
Transurethral resection of the prostate syndrome: almost gone but not forgotten. J Endourol (2009) 1.18
Botox-induced prostatic involution. Prostate (1998) 1.16
Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology (1995) 1.15
The IGF axis in the prostate. Horm Metab Res (1994) 1.08
Natural history of prostatism: urinary flow rates in a community-based study. J Urol (1993) 1.04
Noninvasive methods of diagnosing bladder outlet obstruction in men. Part 1: Nonurodynamic approach. J Urol (2006) 1.03
Differences in initial benign prostatic hyperplasia management between primary care physicians and urologists. J Urol (2009) 1.01
Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int (2012) 0.98
Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials. BMJ (2008) 0.97
The use of the holmium laser in the treatment of benign prostatic hyperplasia. J Endourol (1996) 0.97
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int (2005) 0.97
Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urol (2006) 0.97
Saw palmetto-induced pancreatitis. South Med J (2006) 0.96
Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results. Eur Urol (2006) 0.96
A multicenter, randomized, prospective study of endoscopic laser ablation versus transurethral resection of the prostate. Urology (1995) 0.96
A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. Urology (1995) 0.95
Alpha 2 adrenergic receptors in hyperplastic human prostate: identification and characterization using [3H] rauwolscine. J Urol (1986) 0.94
[The intra-prostatic "partial catheter" (urological spiral) (author's transl)]. Urologe A (1980) 0.93
Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago. Urology (1999) 0.93
Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev (2012) 0.92
A brief review of chronic exercise intervention to prevent autonomic nervous system changes during the aging process. Clinics (Sao Paulo) (2009) 0.92
Evaluation of morbidity of multi-channel pressure-flow studies. Neurourol Urodyn (1999) 0.91
Intraoperative floppy iris syndrome associated with alpha1-adrenergic receptor antagonists. Ann Pharmacother (2008) 0.90
Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. J Urol (2002) 0.90
Transurethral needle ablation (TUNA): safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hyperplasia. Eur Urol (1993) 0.89
Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years. Am J Manag Care (2008) 0.89
Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU Int (2004) 0.88